{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:36:30Z","timestamp":1766468190271,"version":"3.48.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"DOI":"10.7759\/cureus.99882","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:25:53Z","timestamp":1766467553000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Humoral Immune Response Following Two Doses of a Coronavirus Disease 2019 Vector-Based Vaccine During the Initial Rollout in Bangladesh"],"prefix":"10.7759","author":[{"given":"Sharmin","family":"Sultana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Hossain","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abu","family":"Taher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Nazrul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SM Rashed Ul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afzalun","family":"Nessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. WHO COVID-19 dashboard. (2025). Accessed: November 30, 2025: https:\/\/data.who.int\/dashboards\/covid19\/cases?n=o."},{"key":"ref2","unstructured":"COVID-19 Dashboard. COVID-19 dashboard for Bangladesh. (2025). Accessed: October 13, 2025: https:\/\/dashboard.dghs.gov.bd\/pages\/covid19.php."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe8065","article-title":"Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans","volume":"7","author":"Klasse PJ","year":"2021","unstructured":"Klasse PJ, Nixon DF, Moore JP. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Sci Adv. 2021, 7:10.1126\/sciadv.abe8065","journal-title":"Sci Adv"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani M","year":"2021","unstructured":"Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021, 21:475-84. 10.1038\/s41577-021-00578-z","journal-title":"Nat Rev Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer F","year":"2020","unstructured":"Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020, 586:516-27. 10.1038\/s41586-020-2798-3","journal-title":"Nature"},{"key":"ref6","unstructured":"Wikipedia. COVID-19 vaccination in Bangladesh. (2022). Accessed: October 13, 2025: https:\/\/en.wikipedia.org\/wiki\/COVID-19_vaccination_in_Bangladesh."},{"key":"ref7","unstructured":"Directorate General of Health Services. COVID-19 vaccination dashboard for Bangladesh. (2025). Accessed: October 13, 2025: https:\/\/dashboard.dghs.gov.bd\/pages\/covid19-vaccination-update.php."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(21)00168-9","article-title":"Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study","volume":"2","author":"Tut G","year":"2021","unstructured":"Tut G, Lancaster T, Krutikov M, et al.. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. Lancet Healthy Longev. 2021, 2:e544-53. 10.1016\/S2666-7568(21)00168-9","journal-title":"Lancet Healthy Longev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang P","year":"2021","unstructured":"Wang P, Nair MS, Liu L, et al.. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021, 593:130-5. 10.1038\/s41586-021-03398-2","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12690-4","article-title":"Adverse effects and SARS-CoV-2 infection after COVID-19 vaccination among the vaccinated people of Bangabandhu Sheikh Mujib Medical University Hospital in Dhaka, Bangladesh: a pilot study","volume":"15","author":"Sharmin E","year":"2025","unstructured":"Sharmin E, Majumder K, Foyez Ahmed S. Adverse effects and SARS-CoV-2 infection after COVID-19 vaccination among the vaccinated people of Bangabandhu Sheikh Mujib Medical University Hospital in Dhaka, Bangladesh: a pilot study. Sci Rep. 2025, 15:33183. 10.1038\/s41598-025-12690-4","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijregi.2022.04.006","article-title":"Covishield vaccine induces robust immune responses in Bangladeshi adults","volume":"3","author":"Bhuiyan TR","year":"2022","unstructured":"Bhuiyan TR, Akhtar M, Khaton F, et al.. Covishield vaccine induces robust immune responses in Bangladeshi adults. IJID Reg. 2022, 3:211-7. 10.1016\/j.ijregi.2022.04.006","journal-title":"IJID Reg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S335414","article-title":"Antibody response to ChAdOx1-nCoV-19 vaccine among recipients in Bangladesh: a prospective observational study","volume":"14","author":"Hoque A","year":"2021","unstructured":"Hoque A, Barshan AD, Chowdhury FU, Fardous J, Hasan MJ, Khan MA, Kabir A. Antibody response to ChAdOx1-nCoV-19 vaccine among recipients in Bangladesh: a prospective observational study. Infect Drug Resist. 2021, 14:5491-500. 10.2147\/IDR.S335414","journal-title":"Infect Drug Resist"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00680-0","article-title":"Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses","volume":"22","author":"Thiruvengadam R","year":"2022","unstructured":"Thiruvengadam R, Awasthi A, Medigeshi G, et al.. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 2022, 22:473-82. 10.1016\/S1473-3099(21)00680-0","journal-title":"Lancet Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70781","article-title":"The distribution of respiratory viral pathogens among the symptomatic respiratory tract infection patients from Dhaka city in the pre-COVID-19 pandemic era","volume":"16","author":"Islam SR","year":"2024","unstructured":"Islam SR, Ghosh AK, Begum MN, Siddike Shakil MS, Jahan M, Huda AQ. The distribution of respiratory viral pathogens among the symptomatic respiratory tract infection patients from Dhaka city in the pre-COVID-19 pandemic era. Cureus. 2024, 16:e70781. 10.7759\/cureus.70781","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.14415","article-title":"Challenges in the establishment of a biosafety testing laboratory for COVID-19 in Bangladesh","volume":"15","author":"Islam SR","year":"2021","unstructured":"Islam SR, Akther T, Sultana S, et al.. Challenges in the establishment of a biosafety testing laboratory for COVID-19 in Bangladesh. J Infect Dev Ctries. 2021, 15:1833-7. 10.3855\/jidc.14415","journal-title":"J Infect Dev Ctries"},{"key":"ref16","unstructured":"National Institute for Biological Standards and Control (NIBSC). First WHO international standard for anti-SARS-CoV-2 immunoglobulin (human). (2020). Accessed: October 13, 2025: https:\/\/nibsc.org\/documents\/ifu\/20-136.pdf."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3329\/jcmcta.v33i1.66903","article-title":"Pharmacovigilance of COVID-19 vaccine among health care workers in Chittagong Medical College Hospital","volume":"33","author":"Md Erfan Uddin RA","year":"2022","unstructured":"Md Erfan Uddin RA, Sayeed AA, Ghosh AK, Nasreen H, Alam SS, Rana MM, Ghose A. Pharmacovigilance of COVID-19 vaccine among health care workers in Chittagong Medical College Hospital. J Chittagong Med Coll Teach Assoc. 2022, 33:4-8. 10.3329\/jcmcta.v33i1.66903","journal-title":"J Chittagong Med Coll Teach Assoc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-11083-2","article-title":"In-depth analysis of the risk factors for persistent severe acute respiratory syndrome coronavirus 2 infection and construction of predictive models: an exploratory research study","volume":"25","author":"Zhang J","year":"2025","unstructured":"Zhang J, Zhu W, Jiang P, et al.. In-depth analysis of the risk factors for persistent severe acute respiratory syndrome coronavirus 2 infection and construction of predictive models: an exploratory research study. BMC Infect Dis. 2025, 25:699. 10.1186\/s12879-025-11083-2","journal-title":"BMC Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081268","article-title":"Intensity of humoral immune responses, adverse reactions, and post-vaccination morbidity after adenovirus vector-based and mRNA anti-COVID-19 vaccines","volume":"10","author":"Voulgaridi I","year":"2022","unstructured":"Voulgaridi I, Sarrou S, Dadouli A, et al.. Intensity of humoral immune responses, adverse reactions, and post-vaccination morbidity after adenovirus vector-based and mRNA anti-COVID-19 vaccines. Vaccines (Basel). 2022, 10:10.3390\/vaccines10081268","journal-title":"Vaccines (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119497","article-title":"Effectiveness of the BNT162b2 vaccine after recovery from Covid-19","volume":"386","author":"Hammerman A","year":"2022","unstructured":"Hammerman A, Sergienko R, Friger M, et al.. Effectiveness of the BNT162b2 vaccine after recovery from Covid-19. N Engl J Med. 2022, 386:1221-9. 10.1056\/NEJMoa2119497","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-023-02056-5","article-title":"Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort","volume":"20","author":"Huang CF","year":"2023","unstructured":"Huang CF, Jang TY, Wu PH, et al.. Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort. Virol J. 2023, 20:112. 10.1186\/s12985-023-02056-5","journal-title":"Virol J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109072","article-title":"COVID-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk M","year":"2021","unstructured":"Bergwerk M, Gonen T, Lustig Y, et al.. COVID-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021, 385:1474-84. 10.1056\/NEJMoa2109072","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104042","article-title":"Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy","volume":"80","author":"Sormani MP","year":"2022","unstructured":"Sormani MP, Schiavetti I, Inglese M, et al.. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine. 2022, 80:104042. 10.1016\/j.ebiom.2022.104042","journal-title":"EBioMedicine"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020283","article-title":"Immunogenicity and SARS-CoV-2 infection following the fourth BNT162b2 booster dose among health care workers","volume":"11","author":"Shachor-Meyouhas Y","year":"2023","unstructured":"Shachor-Meyouhas Y, Dabaja-Younis H, Magid A, et al.. Immunogenicity and SARS-CoV-2 infection following the fourth BNT162b2 booster dose among health care workers. Vaccines (Basel). 2023, 11:10.3390\/vaccines11020283","journal-title":"Vaccines (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27382","article-title":"Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN\u00ae) and AZD1222 (COVISHIELD(TM) ) recipients: report from the eastern state of India","volume":"94","author":"Dash GC","year":"2022","unstructured":"Dash GC, Subhadra S, Turuk J, et al.. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN\u00ae) and AZD1222 (COVISHIELD(TM) ) recipients: report from the eastern state of India. J Med Virol. 2022, 94:1201-5. 10.1002\/jmv.27382","journal-title":"J Med Virol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/414335-evaluation-of-the-humoral-immune-response-following-two-doses-of-a-coronavirus-disease-2019-vector-based-vaccine-during-the-initial-rollout-in-bangladesh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:25:55Z","timestamp":1766467555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/414335-evaluation-of-the-humoral-immune-response-following-two-doses-of-a-coronavirus-disease-2019-vector-based-vaccine-during-the-initial-rollout-in-bangladesh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.99882","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}